Use of pharmacoeconomics in prescribing research. Part 1: costs - moving beyond the acquisition price for drugs

被引：7

作者：

Robertson, J ^{[1
]}

Lang, D ^{[1
]}

Hill, S ^{[1
]}

机构：

[1] Univ Newcastle, Fac Hlth, Sch Med Practice & Populat Hlth, Newcastle, NSW 2308, Australia

来源：

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | 2003年 / 28卷 / 01期

关键词：

economic evaluation; pharmacoeconomics;

D O I：

10.1046/j.1365-2710.2003.00452.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

This paper addresses pharmacoeconomics in prescribing research and reflects the increasing use of techniques of economic evaluation to aid drug purchasing decisions in a variety of settings - for national drug subsidization programmes, provincial purchasing plans, insurance programmes, and for hospital and area health authority formulary decisions. First, we focus on the cost component of an economic evaluation and discuss methodological issues that are relevant to all pharmacoeconomic analyses.

引用

页码：73 / 79

页数：7

共 20 条

[11] National Institute for Clinical Excellence, 2001, GUID MAN SPONS
[12] NUITJEN MJC, 2001, PHARMACOECONOMICS, V19, P1051
[13] OBrien B, 1996, MED CARE, V34, pDS99
[14] Economics notes - Opportunity cost
Palmer, S
Raftery, J
[J]. BRITISH MEDICAL JOURNAL, 1999, 318 (7197) : 1551 - 1552
[15] Economics notes - Costing in economic evaluation
Raftery, J
[J]. BRITISH MEDICAL JOURNAL, 2000, 320 (7249) : 1597 - 1597
[16] Sculpher M, 2001, EC EVALUATION HLTH C
[17] Siegel JE, 1996, COST EFFECTIVENESS H
[18] Economics notes - Discounting
Torgerson, DJ
Raftery, J
[J]. BRITISH MEDICAL JOURNAL, 1999, 319 (7214) : 914 - 915
[19] 1995, ANN INTERNAL MED, V122, P61
[20] 2002, DEV AN DRG V3 1 AR D

← 1 2 →